The Chhattisgarh health department is taking strong measures to ensure the quality of medicines available to the public. As part of this effort, M/s. Effi Parenterals has been issued a show cause notice, which could lead to their blacklisting due to failures in quality testing.
The health department’s policy mandates that all drug batches supplied to health institutions undergo rigorous quality checks. Before distribution, random samples from each batch are sent to NABL-accredited laboratories for testing, ensuring that only those drugs meeting the required standards are approved for use.
Recent testing at the State Drug Testing and Research Laboratory, Raipur, revealed that batches PGT25451, PGT25450, PGT25480, and PGT25229 of Albendazole Tablets IP 400 mg (Drug Code – D12), supplied by M/s. Effi Parenterals, did not pass the quality tests. Following this, the health department, adhering to its zero-tolerance approach to quality issues, issued a show cause notice to the firm, which may result in blacklisting. The company is also instructed to retrieve the failed batches of medication from all drug warehouses.
Prior to these failed tests, the company had also supplied 14 batches of Albendazole Tablets IP 400 mg, which were distributed to health institutions after successfully passing the NABL tests.